C4 Therapeutics, Inc. reports developments tied to its clinical-stage targeted protein degradation business, including oncology programs designed with its TORPEDO® platform. Recurring company updates cover cemsidomide, an oral IKZF1/3 degrader being studied in relapsed/refractory multiple myeloma, as well as broader degrader-medicine research intended to address disease-causing proteins.
Company news also includes collaboration activity, such as its Roche agreement for degrader-antibody conjugates, along with clinical disclosures, operating and financial results, conference participation, equity inducement grants, and other governance matters under Nasdaq rules.
C4 Therapeutics (Nasdaq: CCCC) reported a narrower third-quarter 2026 net loss while advancing cemsidomide trials for multiple myeloma, a blood cancer. Net loss was $21.8 million, or $0.16 per share, versus $32.2 million, or $0.44 per share, a year earlier. Revenue fell to $8.5 million from $11.2 million. Cash, cash equivalents and marketable securities totaled $274.7 million at September 30; the company expects funding through the end of 2028.
C4T expects Phase 2 MOMENTUM enrollment completion in 1Q 2027 and initial investigator-assessed overall response rate data in 2H 2027. The elranatamab combination trial advanced to a 100 µg safety cohort and 75 µg expansion cohort, with data expected in mid-2027. An additional combination trial remains on track to start in 1H 2027. C4T targets delivery of at least one development candidate to a collaboration partner by year-end 2026.
C4 Therapeutics (Nasdaq: CCCC) announced that management will participate in two investor conferences in November 2026, in Boston and London.
A Guggenheim fireside chat is scheduled for November 9 at 11:00 am ET. A Jefferies presentation and fireside chat will take place on November 17 at 9:30 am GMT/4:30 am ET. Webcasts will be available on the company’s investor website, with replays available for approximately 90 days following the events.
C4 Therapeutics (Nasdaq: CCCC) granted a new employee non-qualified stock options to purchase 85,480 common shares as an employment inducement. The grant was made on November 2, 2026, under Nasdaq Listing Rule 5635(c)(4), with an exercise price equal to the stock’s closing price that day.
The options vest over four years: 25% on the first anniversary of the employee’s start date and the remainder in thirty-six equal monthly installments thereafter. Each vesting date requires continued employment.
C4 Therapeutics (CCCC) expanded its drug-discovery platform with a DNA-encoded library designed to identify molecular glue degraders using a target-first approach.
The library integrates the company’s cereblon-binding compounds into its TORPEDO platform. C4 Therapeutics said the technology has delivered promising initial compounds against selected targets within four months. Testing identified known and novel initial compounds for VAV1, plus compounds for additional undisclosed targets. The company does not plan to advance VAV1 without a partner. Its priorities remain clinical development of cemsidomide and discovery work on undisclosed targets involved in inflammation, neuroinflammation and neurodegenerative diseases.
Insmed (INSM) appointed Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.
Hudson served as CEO of Sanofi from September 2019 through February 2026 and previously led Novartis Pharmaceuticals from 2016 to 2019. Koppikar has served as CFO of Verily Health since April 2023, following his role as executive vice president and CFO at Atara Biotherapeutics from 2018 to 2023. He also serves on the board of C4 Therapeutics (CCCC). Insmed said the appointments add global commercial strategy and financial management experience to its board.
C4 Therapeutics (CCCC) presented new cemsidomide biomarker data from two multiple myeloma combination trials on September 25, 2026. In a Phase 1 trial with dexamethasone, data from 62 heavily pre-treated patients across once-daily dose levels showed T-cell activation and changes in natural killer cell function. Enhanced immune cell function was observed at the 75 µg and 100 µg dose levels.
In an ongoing Phase 1b trial with elranatamab, biomarker data from the first two patients showed expansion and activation of CD8+ effector memory T cells. C4 Therapeutics interpreted the findings as evidence that the combination may help prevent T-cell exhaustion. After a six-patient safety cohort, a review committee declared the 75 µg cemsidomide dose level with elranatamab safe. The trial is moving to a 100 µg dose-escalation safety cohort and a 75 µg expansion cohort. Data from all evaluated cohorts are expected in mid-2027.
C4 Therapeutics (CCCC) will present new biomarker data from its Phase 1 trial of cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting.
The poster will detail immunomodulatory effects on T cells and natural killer (NK) cells across once-daily dose levels evaluated in the study, which the company says further support cemsidomide’s potential as a combination partner for immune-based therapies. The meeting will be held in Glasgow, Scotland from September 23–26, 2026.
The poster, titled “T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And Potent MonoDAC® Degrader, In Relapsed/Refractory Multiple Myeloma: Biomarker Results From CFT7455-1101 Arm B2 Cohort,” is scheduled for September 25, 2026, from 12 pm–1 pm BST / 7 am–8 am ET and will be presented by Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine at C4 Therapeutics.
C4 Therapeutics (Nasdaq: CCCC) reported second quarter 2026 revenue of $6.6 million versus $6.5 million a year earlier, with a net loss of $23.6 million ($0.18 per share) compared to $26.0 million ($0.37 per share) in 2025. R&D and G&A expenses declined slightly year over year.
Cash, cash equivalents and marketable securities totaled $300.4 million at June 30, 2026, supported by $33.5 million raised via an at-the-market program and a $20 million upfront payment from a new degrader‑antibody conjugate collaboration with Roche. According to C4 Therapeutics, this cash runway is expected to fund operations into the end of 2028.
Clinically, updated Phase 1 data for cemsidomide in multiple myeloma showed overall response rates of 40% and 53% at the two highest doses with no cemsidomide‑related discontinuations, which the company says support a differentiated profile. Multiple ongoing and planned cemsidomide trials remain on track, with key data readouts expected in 2027.
C4 Therapeutics (Nasdaq: CCCC) reported that the independent directors on its Organization, Leadership and Compensation Committee approved an inducement grant of non-qualified stock options to purchase 162,880 shares of common stock for one new employee, effective August 10, 2026.
According to C4 Therapeutics, the grant was made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The exercise price equals the closing price of C4T’s common stock on the grant date. The options vest over four years: 25% after one year, then the remainder in 36 equal monthly installments, contingent on continued employment.
C4 Therapeutics (Nasdaq: CCCC) reported updated Phase 1 data for cemsidomide, an oral IKZF1/3 degrader, in relapsed/refractory multiple myeloma at the EHA 2026 Congress.
At the 100 µg RP2D, overall response rate was 53%, with MRD-negative complete responses, a 7.9‑month median response duration and a generally manageable safety profile in heavily pretreated patients.